Results 251 to 260 of about 499,069 (309)
Some of the next articles are maybe not open access.

Interleukin 2 receptors

Leukemia Research, 1990
Interleukin 2 receptors (IL-2-R) are composed of (at least) two chains: the alpha chain (or p55 or Tac) and the beta chain (or p70 or p75). The association of both chains constitutes high affinity IL2-R complexes (Kd congruent to 10-100 pM), whereas the alpha-chain or the beta chain alone bind IL-2 with low (Kd congruent to 5-50 nM) and intermediate ...
M, Allouche   +5 more
openaire   +2 more sources

The Human Interleukin-2 Receptor

Annual Review of Immunology, 1986
In 1976, Morgan et al first reported the presence of a T-cell growth­ promoting activity in the supernatants of activated T-cell cultures; they denoted this T-cell growth factor (TCGF) (1). In subsequent years, TCGF was characterized as a distinct biochemical entity and found to be a 15,500dalton glycoprotein (2).
W C, Greene, W J, Leonard
openaire   +3 more sources

The human interleukin-2 receptor

Journal of Cell Science, 1985
ABSTRACT Complementary DNAs corresponding to the human receptor for interleukin-2 (IL-2) have been molecularly cloned, sequenced, and expressed in both COS-1 and L cells. The human genome appears to contain a single structural gene for this receptor located on the short arm of chromosome 10 (band 14-15).
W C, Greene   +3 more
openaire   +2 more sources

Regulation of Interleukin 2 Receptor Expression by Interleukin 2

Scandinavian Journal of Immunology, 1986
The regulatory influence of Interleukin 2 (IL‐2) on the expression of IL‐2 receptors (IL.‐2R) was studied using long‐term cultured T‐cell lines and recombinant IL‐2 (r‐IL‐2). Three T‐cell lines with different growth requirements were used as model systems: insulin‐specific BK‐BI‐1.2 cells express IL‐2R transiently after antigenic restimulation ...
A B, Reske-Kunz   +3 more
openaire   +2 more sources

Interleukin 2/interleukin 2 receptor system in type 1 diabetes

Diabetes Research and Clinical Practice, 1989
There is increasing evidence that cellular immune abnormalities are involved in the pathogenesis of type 1 diabetes mellitus. The non-obese diabetic (NOD) mouse, a model of human type 1 diabetes, develops mononuclear cell infiltration of its pancreatic islets (insulitis), leading to /3 cell destruction and overt diabetes [l]. In recent studies, most of
N, Hatamori   +4 more
openaire   +2 more sources

Interleukin-2 Receptors

1985
Interleukin-2 (IL-2) is a lymphokine synthesized by some T-cells following activation. Resting T-cells do not express IL-2 receptors but receptors are rapidly expressed on T-cells following the interaction of antigens, mitogens, or monoclonal antibodies with the antigen specific T-cell receptor complex.
Thomas A. Waldmann   +6 more
openaire   +1 more source

Interleukin-2 receptors in infectious mononucleosis

Immunology Letters, 1989
The majority of peripheral blood mononuclear cells (PBMC) from acute-phase infectious mononucleosis (IM) patients express high levels of T10 (CD38) and HLA-DR surface antigens, which are markers characteristic of activated T cells. However, Tac antigen (p55) expression on these cells was not detectable by flow cytometric immunofluorescence, and only a ...
C, Schmidt   +5 more
openaire   +2 more sources

Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T-lymphocytes in vitro

Pathology, 1991
Following activation in vitro, peripheral blood mononuclear cells (PBMC) express cell-associated interleukin-2 receptors (IL2R). The present study was undertaken to define the proportion of T lymphocyte subsets that express the IL2R (CD25 antigen) upon different mitogenic stimulation.
Lai, FM, Leung, JCK, Lai, KN
openaire   +4 more sources

The released interleukin 2 receptor binds interleukin 2 efficiently.

The Journal of Immunology, 1986
Abstract The released interleukin 2 receptor (IL 2R) molecule was characterized in order to clarify its biochemical structure and to determine its functional capacity. Enzymatic digestions demonstrated that the released IL 2R, like the cell surface IL 2R, is a complex glycoprotein, modified by the addition of both N- and O-linked ...
L A, Rubin, G, Jay, D L, Nelson
openaire   +2 more sources

INTERLEUKIN 2 RECEPTOR-DIRECTED IMMUNOSUPPRESSIVE THERAPY

1987
An ideal antirejection therapy should, of course, be effective in controlling rejection as well as selectively target only those T-cells that are committed to participate in rejection of the donor graft. Conventional immunosuppressive drugs exact unwanted side effects upon non-lymphoid tissues. The introduction of monoclonal antibodies as pharmacologic
T. B. Strom   +9 more
openaire   +1 more source

Home - About - Disclaimer - Privacy